|
1
|
Wong KH, Mang OW, Au KH and Law SC: .
Incidence, mortality, and survival trends of ovarian cancer in Hong
Kong, 1997 to 2006: a population-based study. Hong Kong Med J.
18:466–474. 2012.PubMed/NCBI
|
|
2
|
Helzlsouer KJ, Erlinger TP and Platz EA:
C-reactive protein levels and subsequent cancer outcomes: results
from a prospective cohort study. Eur J Cancer. 42:704–707. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Balkwill F and Mantovani A: Inflammation
and cancer: back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hefler LA, Zeillinger R, Grimm C, et al:
Preoperative serum vascular endothelial growth factor as a
prognostic parameter in ovarian cancer. Gynecol Oncol. 103:512–517.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tempfer C, Zeisler H, Sliutz G, et al:
Serum evaluation of interleukin 6 in ovarian cancer patients.
Gynecol Oncol. 66:27–30. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zeimet AG, Widschwendter M, Knabbe C, et
al: Ascitic interleukin-12 is an independent prognostic factor in
ovarian cancer. J Clin Oncol. 16:1861–1868. 1998.PubMed/NCBI
|
|
7
|
Friedlander ML: Prognostic factors in
ovarian cancer. Semin Oncol. 25:305–314. 1998.PubMed/NCBI
|
|
8
|
Winter-Roach BA, Kitchener HC and Lawrie
TA: Adjuvant (post-surgery) chemotherapy for early stage epithelial
ovarian cancer. Cochrane Database Syst Rev.
3:CD0047062012.PubMed/NCBI
|
|
9
|
Marchetti CI, Pisano C, Facchini G, et al:
First-line treatment of advanced ovarian cancer: current research
and perspectives. Expert Rev Anticancer Ther. 10:47–60. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Marnell L, Mold C and Du Clos TW:
C-reactive protein: ligands, receptors and role in inflammation.
Clin Immunol. 117:104–111. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Allavena P, Garlanda C, Borrello MG, Sica
A and Mantovani A: Pathways connecting inflammation and cancer.
Curr Opin Genet Dev. 18:3–10. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lundin E, Dossus L, Clendenen T, et al:
C-reactive protein and ovarian cancer: a prospective study nested
in three cohorts (Sweden, USA, Italy). Cancer Causes Control.
20:1151–1159. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Siemes C, Visser LE, Coebergh JW, et al:
C-reactive protein levels, variation in the C-reactive protein
gene, and cancer risk: the Rotterdam Study. J Clin Oncol.
24:5216–5222. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Il'yasova D, Colbert LH, Harris TB, et al:
Circulating levels of inflammatory markers and cancer risk in the
health aging and body composition cohort. Cancer Epidemiol
Biomarkers Prev. 14:2413–2418. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Trichopoulos D, Psaltopoulou T, Orfanos P,
Trichopoulou A and Boffetta P: Plasma C-reactive protein and risk
of cancer: a prospective study from Greece. Cancer Epidemiol
Biomarkers Prev. 15:381–384. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gockel I, Dirksen K, Messow CM and
Junginger T: Significance of preoperative C-reactive protein as a
parameter of the perioperative course and long-term prognosis in
squamous cell carcinoma and adenocarcinoma of the oesophagus. World
J Gastroenterol. 12:3746–3750. 2006.PubMed/NCBI
|
|
17
|
Hashimoto K, Ikeda Y, Korenaga D, et al:
The impact of preoperative serum C-reactive protein on the
prognosis of patients with hepatocellular carcinoma. Cancer.
103:1856–1864. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McMillan DC, Canna K and McArdle CS:
Systemic inflammatory response predicts survival following curative
resection of colorectal cancer. Br J Surg. 90:215–219. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brown DJ, Milroy R, Preston T and McMillan
DC: The relationship between an inflammation-based prognostic score
(Glasgow Prognostic Score) and changes in serum biochemical
variables in patients with advanced lung and gastrointestinal
cancer. J Clin Pathol. 60:705–708. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Polterauer S, Grimm C, Tempfer C, et al:
C-reactive protein is a prognostic parameter in patients with
cervical cancer. Gynecol Oncol. 107:114–117. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Anastasi E, Marchei GG, Viggiani V, et al:
HE4: a new potential early biomarker for the recurrence of ovarian
cancer. Tumour Biol. 31:113–119. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Klug TL, Bast RC Jr, Niloff JM, Knapp RC
and Zurawski VR Jr.: Monoclonal antibody immunoradiometric assay
for an antigenic determinant (CA 125) associated with human
epithelial ovarian carcinomas. Cancer Res. 44:1048–1053.
1984.PubMed/NCBI
|
|
23
|
Schilthuis MS, Aalders JG, Bouma J, et al:
Serum CA 125 levels in epithelial ovarian cancer: relation with
findings at second-look operations and their role in the detection
of tumour recurrence. Br J Obstet Gynaecol. 94:202–207. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Santillan A, Garg R, Zahurak ML, et al:
Risk of epithelial ovarian cancer recurrence in patients with
rising serum CA-125 levels within the normal range. J Clin Oncol.
23:9338–9343. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Howe HL, Tung KH, Coughlin S,
Jean-Baptiste R and Hotes J: Race/ethnic variations in ovarian
cancer mortality in the United States, 1992–1997. Cancer. 97(10
Suppl): 2686–2693. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Benedet JL, Bender H, Jones H III, Ngan HY
and Pecorelli S: FIGO staging classifications and clinical practice
guidelines in the management of gynecologic cancers. FIGO Committee
on Gynecologic Oncology. Int J Gynaecol Obstet. 70:209–262. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
McSorley MA, Alberg AJ, Allen DS, et al:
C-reactive protein concentrations and subsequent ovarian cancer
risk. Obstet Gynecol. 109:933–941. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ness RB: Endometriosis and ovarian cancer:
thoughts on shared pathophysiology. Am J Obstet Gynecol.
189:280–294. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tung KH, Wilkens LR, Wu AH, et al: Effect
of anovulation factors on pre- and postmenopausal ovarian cancer
risk: revisiting the incessant ovulation hypothesis. Am J
Epidemiol. 161:321–329. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shacter E and Weitzman SA: Chronic
inflammation and cancer. Oncology (Williston Park). 16:217–226.
2002.PubMed/NCBI
|
|
31
|
McMillan DC, Elahi MM, Sattar N, et al:
Measurement of the systemic inflammatory response predicts
cancer-specific and non-cancer survival in patients with cancer.
Nutr Cancer. 41:64–69. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hefler LA, Concin N, Hofstetter G, et al:
Serum C-reactive protein as independent prognostic variable in
patients with ovarian cancer. Clin Cancer Res. 14:710–714. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hefler-Frischmuth K, Hefler LA, Heinze G,
et al: Serum C-reactive protein in the differential diagnosis of
ovarian masses. Eur J Obstet Gynecol Reprod Biol. 147:65–68. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lu Y, Yin F and Chen Z: Prognostic value
of preoperative serum C-reactive protein in patients with
epithelial ovarian cancer. Progress inObstetrics and Gynecology.
17:489–492. 2008.
|
